ACT Capital Management’s Novavax NVAX Stock Holding History

ACT Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,300	Closed	-$2.19M	–	123
2021 Q2	$2.19M	Buy	+10,300	New	+$1.89M	1.12%	19

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACT Capital Management's NVAX Position: Q3 2021 in Review

ACT Capital Management sold out of Novavax (NVAX) in Q3 2021, closing a stake of 10,300 shares — an estimated $2.19M sold.

ACT Capital Management first reported a position in NVAX in Q2 2021 and held it in 1 quarter. The position peaked at $2.19M in Q2 2021. 443 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

ACT Capital Management reported no remaining Novavax position as of Q3 2021 after selling out during the quarter.
ACT Capital Management sold 10,300 Novavax shares in Q3 2021, an estimated $2.19M.
ACT Capital Management first reported a position in Novavax in Q2 2021 and held it in 1 quarter.
ACT Capital Management's Novavax position peaked at $2.19M in Q2 2021.
443 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.